Pharmacogenomic Insights: The Role of CYP2D6 Allelic Variants in Drug Metabolism Among COVID-19 Patients With Comorbidities
This study highlights the diverse clinical profiles of COVID-19 patients with different CYP2D*6 variants, particularly the association between <i>CYP2D6</i>*5 heterozygosity and a reduced lymphocyte count.
Authors
- Vefa Çakmak (ORCID: https://orcid.org/0000-0001-7002-5594)
- Alten Oskay (ORCID: https://orcid.org/0000-0003-4373-6280)
- Yasemin Adalı (ORCID: https://orcid.org/0000-0002-6314-4816)
- İbrahim Türkçüer (ORCID: https://orcid.org/0000-0001-8342-4615)
- Aylin Köseler (ORCID: https://orcid.org/0000-0003-4832-0436)
- Murat Seyit (ORCID: https://orcid.org/0000-0002-8324-9471)
- Atakan Yılmaz (ORCID: https://orcid.org/0000-0002-9773-5681)
- Mert Özen (ORCID: https://orcid.org/0000-0001-6653-3756)
Institutions
- Queen's University Belfast (GB)
- Pamukkale University (TR)
Publication Details
- Journal
- In Vivo
- Published
- 2025-10-29
- DOI
- https://doi.org/10.21873/invivo.14154
- Primary Topic
- Pharmacogenetics and Drug Metabolism
- Type
- article
- Field-Weighted Citation Impact
- 0.00